SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob L who wrote (413)12/2/1999 9:10:00 AM
From: biowa  Read Replies (1) of 666
 
Bob L,

<<How are they going to get clinical approval without dosimetry when the phase III used it?>>

If the dosimetry doesn't guide the treatment, then it may be considered merely another assessment technique. Zevalin is given in a dosage independent of dosimetry in the PIII isn't it? The big caveat to this is if the data shows a significant difference in response to the set dosage based on dosimetry.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News